-
-
Analgesic potential of PF-06372865, an alpha 2/alpha 3/alpha 5 subtype-selective GABA(A) partial agonist, in humans
-
-
Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs
-
-
The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study
-
-
Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties
-
-
No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery
-
-
Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects
-
-
Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models
-
-
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects
-
-
Quantifying Beta‐Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling
-
-
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica
-
-
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
-
-
NOVEL IN VIVO HUMAN MODEL FOR TRANSIENT MITOCHONDRIAL DYSFUNCTION: SIMVASTATIN-INDUCED MITOCHONDRIAL DYSFUNCTION IN HEALTHY SUBJECTS AND ITS REVERSIBILITY BY UBIQUINOL
-
-
NOVEL IN VIVO HUMAN MODEL FOR TRANSIENT MITOCHONDRIAL DYSFUNCTION: SIMVASTATIN-INDUCED MITOCHONDRIAL DYSFUNCTION IN HEALTHY SUBJECTS AND ITS REVERSIBILITY BY UBIQUINOL
-
-
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
-
-
Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling
-
-
THE USE OF A BATTERY OF PAIN MODELS TO DETECT ANALGESIC PROPERTIES OF COMPOUNDS: A TWO-PART, FOUR-WAY, RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY
-
-
The Effects of the Nonselective Benzodiazepine Lorazepam and the alpha(2)/alpha(3) Subunit-Selective GABA(A) Receptor Modulators AZD7325 and AZD6280 on Plasma Prolactin Levels
-
-
STABILITY ANALYSIS OF CLUSTERING OF NORRIS' VISUAL ANALOG SCALE
-
-
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine
-
-
Pharmacokinetics and central nervous system effects of the novel dual NK1/NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers
-
-
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans